|
|
|
17.03.26 - 21:03
|
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption (Business Wire)
|
|
|
Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testingFREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role.
The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific leadership, Personalis developed and accelerated adoption of the NeXT Personal® platform, which set a new industry benchmark for ultrasensitive MRD testing, detecting cancer at levels far below those previously achievable.
"Personalis is no longer just participating in the MRD market;...
|
|
|
|
|
|
|
|
|
|
|
26.02.26 - 22:03
|
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights (Business Wire)
|
|
|
Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests and full year increased nearly 400% to 16,233 tests
Secured Medicare coverage for breast and lung cancer surveillance, validating ultrasensitive MRD technology
Strong cash position of approximately $240 million provides capital for commercial expansion
Full year 2026 revenue guidance of $78 to $80 million, driven by expected growth of approximately 5x for clinical revenue
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025 and recent business highlights and provided financial guidance for the full year 2026.
Fourth Quarter and Recent Strategic and Operational Highlights
Secured Milestone Medicare Coverages for Breast & Lung Cancer: Received Medicare coverage approval in the fourth quarter for the surveillance of cancer recurrence in breast cancer patients, and also, rec...
|
|
|
12.02.26 - 22:03
|
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
|
|
|
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management...
|
|
|
|
|
|
|
|
|
|
|
08.01.26 - 14:06
|
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights (Business Wire)
|
|
|
Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests; full year volume of 16,233 tests outperforms initial 2025 projections
Strong cash position of approximately $240 million provides capital for commercial expansion
Secured pivotal Medicare coverage for breast cancer surveillance, validating ultrasensitive MRD technology
Preliminary Q4 revenue of $17 to $18 million; preliminary full year revenue of $69 to $70 million
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025.
Fourth Quarter Strategic and Operational Highlights
Secured Milestone Medicare Coverage: Received Medicare coverage approval for the surveillance of cancer recurrence in breast cancer patients, a key catalyst for clinical revenue and market share growth in the MRD space.
Published Landmark TRACERx Data: Announced the publicati...
|
|
|
|
|
|
|
|
|
|
|
|
|
04.11.25 - 22:03
|
Personalis Reports Third Quarter 2025 Financial Results (Business Wire)
|
|
|
Company Advances "Win-in-MRD" Strategy with Compelling Clinical Trial Data and Increasing Physician Adoption of NeXT Personal® Platform
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by significant operational momentum in its "Win-in-MRD" strategy, headlined by increasing clinical tests delivered and robust clinical evidence generation.
Third Quarter 2025 and Recent Business Highlights
Accelerated Clinical Adoption: Delivered 4,388 clinical tests, demonstrating robust 26% sequential increase over Q2 2025 and a 364% year-over-year growth fueled by increasing physician adoption of the NeXT Personal platform for cancer monitoring.
Submitted for Medicare Lung Cancer Coverage. Submitted a third dossier for Medicare coverage. The Company has three pending indications and remains confident its evidence will me...
|
|
|
|
|
15.09.25 - 23:36
|
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on September 15, 2025, a non-qualified stock option to purchase an aggregate of 440,000 shares of its common stock to Personalis' new Senior Vice President, Chief Information Officer under Personalis' 2020 Inducement Plan.
The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual's entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Personalis is making this announcement as required by Nasdaq rules.
The inducement stock option granted on September 15, 2025 has an exercise price of $5.93 per share, which is equal to the closing price of Personalis' common stock on the grant date. The inducement stock op...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
